ArriVent BioPharma, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. ArriVent is a clinical-stage biopharmaceutical company developing firmonertinib and other cancer therapies. It has no products approved for sale and has generated no revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $17.0 million | $10.2 million |
| General and administrative expense | $3.7 million | $1.9 million |
| Total operating expenses / operating loss | $20.7 million | $12.2 million |
| Interest income | $3.3 million | None |
| Net loss | $17.4 million | $12.2 million |
| Net loss per share, basic and diluted | $0.70 | $9.45 |
| Net cash used in operating activities | $18.6 million | $16.9 million |
| Cash and cash equivalents at March 31 | $317.4 million | $150.4 million at December 31, 2023 |
R&D spending rose $6.7 million, chiefly from a $5.2 million increase in the FURVENT Phase 3 trial, alongside higher personnel and other firmonertinib costs. G&A increased $1.8 million, primarily from professional services and personnel. The increase in net loss was partly offset by interest income. Operating margins are not meaningful because the company has no revenue.
In January 2024, the company completed its IPO, selling 11,180,555 shares at $18 per share and reporting $183.2 million of net proceeds. Preferred shares converted into common stock; 33,493,750 common shares were outstanding at March 31. Cash increased by $167.0 million during the quarter, largely reflecting IPO financing. The company reported no debt; liabilities were primarily accounts payable, accrued expenses and operating leases. Lease liabilities totaled $0.3 million.
Business developments, outlook and risks
- Firmonertinib is being evaluated across EGFR-mutant non-small cell lung cancer. The company is conducting the global pivotal Phase 3 FURVENT trial in first-line patients with locally advanced or metastatic EGFR exon 20 insertion NSCLC. The FDA granted Breakthrough Therapy Designation in October 2023; the company reported Orphan Drug Designation in February 2024.
- The filing describes interim FAVOUR trial results from a study conducted by Allist in China: 22 of 28 patients (79%) had tumor-size reductions of at least 30%, with a reported median duration of response of 15.2 months. These are interim results and may not predict final outcomes; firmonertinib is investigational and is not FDA-approved.
- Management expects continued losses as development advances. It stated that existing cash should fund planned operations into 2026; the financial-statement note separately says cash is sufficient for at least 12 months from issuance. These are estimates subject to clinical, regulatory, spending and financing uncertainty. No formal revenue or earnings guidance is provided.
- Under the Allist license, potential obligations include up to $105 million in clinical and regulatory milestones, up to $655 million in sales milestones, and tiered royalties. No clinical milestones were achieved in Q1. A separate Aarvik agreement could entail additional milestone payments and royalties if options are exercised.
- The company reported no material change to previously disclosed risk factors and no known legal proceedings expected to have a material adverse effect. Clinical success, regulatory approval, commercialization, funding needs, competition and license obligations remain significant uncertainties.
- Disclosure controls were deemed ineffective because of material weaknesses in internal control over financial reporting. Remediation is underway, but the company cautioned it may not be successful.
Important facts for investors to verify
- Progress, enrollment, costs and results of FURVENT and other firmonertinib studies; distinguish interim FAVOUR findings from final clinical results.
- Whether the projected cash runway into 2026 remains achievable as trial spending and public-company costs increase.
- Reconciliation of reported IPO net proceeds of $183.2 million with $185.6 million of financing cash flow reported for the quarter.
- Remediation and testing of the disclosed material weaknesses in internal controls.
- Potential milestone and royalty exposure under the Allist license and any future Aarvik option exercise.